Mizuho raised the firm’s price target on Arcutis Biotherapeutics to $17 from $16 and keeps a Buy rating on the shares post the Q4 report. The company reported a strong end to 2023 and there is potential for upward consensus revision, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARQT:
- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Arcutis Biotherapeutics reports Q4 EPS (72c), consensus (77c)
- Arcutis Biotherapeutics price target raised to $16 from $8 at Mizuho
- Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
- Arcutis Biotherapeutics Launches Stock Option Exchange Program
